Last reviewed · How we verify

Imovax Rabies vaccine

U.S. Army Medical Research and Development Command · Phase 1 active Biologic

Imovax Rabies vaccine is a Biologic drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 1 development.

At a glance

Generic nameImovax Rabies vaccine
SponsorU.S. Army Medical Research and Development Command
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Imovax Rabies vaccine

What is Imovax Rabies vaccine?

Imovax Rabies vaccine is a Biologic drug developed by U.S. Army Medical Research and Development Command.

Who makes Imovax Rabies vaccine?

Imovax Rabies vaccine is developed by U.S. Army Medical Research and Development Command (see full U.S. Army Medical Research and Development Command pipeline at /company/u-s-army-medical-research-and-development-command).

What development phase is Imovax Rabies vaccine in?

Imovax Rabies vaccine is in Phase 1.

Related